Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BBT-207 |
Synonyms | |
Therapy Description |
BBT-207 is a 4th-generation EGFR inhibitor with activity against EGFR T790M and C797S, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 4018). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BBT-207 | BBT207|BBT 207 | EGFR Inhibitor 4th gen 16 | BBT-207 is a 4th-generation EGFR inhibitor with activity against EGFR T790M and C797S, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 4018). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05920135 | Phase Ib/II | BBT-207 | First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI | Recruiting | USA | 1 |